Digging Into The Data: Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)


Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) closed its last session at $5.72. The stock traded within a range of $5.40 and $5.81. The company operates in the Healthcare sector with a market capitalization of 426250. Trading volume for Arrowhead Pharmaceuticals, Inc. was 5.11 Million in its previous trading session. Currently, Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) has an average volume of 1.4 Million.

Company Profile

Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company which develops novel drugs to treat intractable diseases primarily in the United States. The company’s proprietary Dynamic Polyconjugate platform develops drugs based on the RNA interference mechanism which silences disease-causing genes. Its products include ARC-520, ARC-521, ARC-AAT, ARC-F12, ARC-HIF2 and ARC-LPA which are in different clinical trial phase. Arrowhead Pharmaceuticals, Inc., formerly known as Arrowhead Research Corporation, is headquartered in Pasadena, California.

Analyst Views

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) received a Buy rating from 0 analysts. 0 analysts gave its stock an Outperform rating. 1 analysts say it’s a Hold while 0 analysts provided their expert opinion as Sell.

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) touched its 1-Year High price of $6.25 on 01/12/18 and its 1-Year Low price of $1.42 on 05/31/17.

EPS & Financials

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) reported its EPS in the last quarter as $-0.15/Share lagging the analyst estimate of $-0.1/Share by a difference of $-0.05. This showed a surprise of -50% in the last quarter earnings.

For the current quarter, 4 analysts are projecting a mean EPS of $-0.16/share. According to their observations and findings, the stock could provide a high EPS of $-0.12/share and a low EPS of $-0.23/share.

Analysts believe that the company has the potential to earn average revenue of $7.27 Million for the current quarter. According to their predictions high & low revenue estimates are 8.71 Million and 4.38 Million respectively.

Technical Analysis

By taking a look at the stock’s current statistics it can gauged that the stock candle is BULLISH with HIGH volatility. Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) has a 20-Day average volume of 2.54 Million. According to today’s trading volume Arrowhead Pharmaceuticals, Inc. is ABOVE its 20-Day Avg. volume with the stock showing ABOVE Abnormal volume in the past 150 days.

Moving average convergence divergence (MACD) shows that the stock is on a PRICE RELATIVITY trend. The trend for the past 10-days shows that the company was in BULLISH territory while an analysis of the last 40-Day trend shows a BULLISH signal. The 100-Day trend also shows a BULLISH trend as well.

The company currently has an insider ownership of 10.83 Percent and Institutional ownership of 20.2 Percent. The return on assets stands at -28.1%, Return on Equity currently is -37.9% and the Return on Investment value is -44.1%.

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) gross margin percentage stands at 0% while its operating margin for the past trailing twelve month is 0 percent and its overall profit margin (ttm) is 0 Percent. The stock is currently moving above its 20-Day Simple Moving Average of 32.99% with a 50-Day Simple Moving Average of 48.31 percent. As of today, the company has a SMA200 (200-day simple moving average) of 111.93 Percent. The Stock has YTD (year to date) performance of 55.43 percent.

The TTM operating margin for the company stands at 0%. The return on invested capital is at -44.1%, which is good, compared to its peers. The Free Cash Flow or FCF margin is 0.

The company’s stock is currently moving with a +ve distance from the 200 day SMA of approximately 111.93%, and has a solid year to date (YTD) performance of 55.43% which means that the stock is constantly adding to its value from the previous fiscal year end price.